Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, Astellas Pharma and Pfizer Inc. (NYSE:PFE) announced positive topline results from the Phase 3 EV-304 clinical trial (also called KEYNOTE-B15). This study showed that the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) improves survival outcomes for patients with muscle-invasive bladder cancer/MIBC who are eligible for cisplatin-based chemotherapy. Used as a peri ...

As the looming patent cliff approaches, some major blockbuster drugs are set to lose their exclusivity, with pharma companies making moves to try and reduce the impact. Patent expiry is a phenomenon that haunts every pharmaceutical company, with the loss of market exclusivity often causing a dramatic dip in a company’s profits. This can be particularly challenging for companies whose drug is one of their best-sellers – having the potential to wipe billions from revenue figures. With a particularly large ...

Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer’s 2026 guidance revealed a steeper erosion of its COVID-19 franchise than previously projected, leading the firm to trim its near-term financial forecasts. The focus has now shifted to the company’s obesity strategy; investors are awaiting trial results from the rec ...

Pyxis Oncology Inc. (NASDAQ:PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).The update includes preliminary data from both the Phase 1 monotherapy study in second line (2L+) R/M HNSCC and the Phase 1/2 study evaluating MICVO in combination with Merck & Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab), in (first and second line) 1L/2L+ R/M HNSCC.The data reported below reflec ...

Core Insights - Adagene Inc. (ADAG) received Fast Track designation from the FDA for its lead immuno-oncology candidate, muzastotug (ADG126), in combination with Merck's Keytruda for treating adult patients with microsatellite-stable metastatic colorectal cancer (MSS mCRC) without active liver metastases [1][6] - Following the announcement, ADAG shares increased by 13.8% [1][7] - The Fast Track designation aims to expedite the development and review of therapies for serious diseases with unmet medical needs [2] Company Overview - Muzastotug is a next-generation anti-CTLA-4 antibody developed using proprietary SAFEbody masking technology, which may improve survival and quality of life compared to conventional therapies [5][7] - The ongoing phase II study has primary and secondary endpoints focused on overall response rate, duration of response, progression-free survival, and overall survival [6][8] - A phase III study is planned to start in 2027, contingent on continued positive clinical results [8] Market Performance - Over the past year, ADAG's shares have declined by 6.9%, contrasting with a 16.3% rise in the industry [4] - The Fast Track designation allows for more frequent interactions with the FDA and potential rolling reviews of future marketing applications [8]

® SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint ...

Core Viewpoint - Pliant Therapeutics is gaining attention due to promising interim trial results for its cancer therapy, PLN-101095, despite a significant decline in its stock price [1][8]. Group 1: Trial Results - Pliant Therapeutics released interim data from its Phase 1 dose escalation trial of PLN-101095, which was evaluated in combination with Merck's Keytruda for patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors [2]. - In a heavily pretreated patient population, PLN-101095 demonstrated antitumor activity, with four responders identified, including one confirmed complete response and three partial responses [3][4]. - Clinical responses were observed in various cancer types, including cholangiocarcinoma, melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer [4]. Group 2: Patient Outcomes - The median time on treatment for patients was 15 months, with 60% of secondary refractory patients showing stable disease or tumor reduction [5]. - All responding patients exhibited significant increases in plasma interferon gamma (IFN-γ) levels after a 14-day monotherapy run-in period, while non-responders did not show meaningful increases [5]. Group 3: Safety and Future Plans - PLN-101095 was generally well tolerated across all tested doses and exhibited a dose-dependent pharmacokinetic profile [6]. - Pliant plans to accelerate the development of PLN-101095 with a Phase 1b indication expansion trial set to begin in 2026, focusing on non-small cell lung cancer and other tumor types [7].

Core Insights - AIM ImmunoTech will participate in the Virtual Investor Closing Bell Series on December 4, 2025, featuring CEO Thomas K. Equels [1] - The discussion will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, particularly the DURIPANC clinical trial in collaboration with AstraZeneca for metastatic pancreatic cancer [2] - The importance of a completed Phase 2 clinical trial with Merck, showing the combination of Ampligen and Keytruda was well-tolerated and beneficial for advanced recurrent ovarian cancer, will also be highlighted [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]

Core Insights - Eli Lilly has achieved a market capitalisation of $1 trillion, becoming the first healthcare company to reach this milestone, previously dominated by technology firms [1][2] - The surge in Eli Lilly's market value is primarily driven by the unprecedented demand for its weight loss drugs, particularly tirzepatide [1][4] Financial Performance - Eli Lilly's share price closed at $1,059.70 on November 21, reflecting a 27% increase since January 2025, although it slightly retreated to $1,056.77 by November 24 [2] - The S&P 500 pharmaceutical index has risen by 19% since the beginning of September, indicating a growing investor interest in pharmaceutical stocks [3] Product Success - Tirzepatide, marketed as Zepbound and Mounjaro, has significantly contributed to Eli Lilly's success, with Mounjaro generating $6.5 billion in Q3 2025, a 109% increase from Q3 2024, and Zepbound achieving $3.6 billion, up 185% from the same period [4][5] - GlobalData forecasts that the combined sales of Zepbound and Mounjaro will reach $64 billion by 2031 [5] Competitive Landscape - Tirzepatide's growth has positioned Eli Lilly ahead of its main competitor, Novo Nordisk, which has seen a decline in share prices despite being first to market with semaglutide [6] - Tirzepatide's dual-action mechanism offers better efficacy compared to semaglutide, contributing to its market success [6] - The sales performance of tirzepatide has surpassed that of MSD's Keytruda, which has been the top-selling drug globally in recent years [7]

Core Viewpoint - PDS Biotechnology Corporation has completed the VERSATILE-002 Phase 2 trial for PDS0101 in combination with pembrolizumab, showing promising results that lead the company to seek an expedited approval pathway in the ongoing VERSATILE-003 Phase 3 trial [1][2][3]. Clinical Update - The VERSATILE-002 trial demonstrated a median overall survival (mOS) of 39.3 months for patients with CPS ≥ 1, with a 95% confidence interval lower limit of 23.9 months [4]. - Progression-free survival (PFS) was reported at 6.3 months for the same patient group [4]. - The company plans to amend the ongoing VERSATILE-003 trial to potentially reduce its size while maintaining statistical power, with mOS remaining the primary endpoint for full FDA approval [4][3]. Financial Results - For Q3 2025, the company reported a net loss of $9.0 million, or $0.19 per share, a decrease from a net loss of $10.7 million, or $0.29 per share, in Q3 2024 [5][16]. - Research and development expenses were $4.6 million, down from $6.8 million in the same quarter of the previous year, attributed to lower manufacturing and clinical expenses [6][16]. - General and administrative expenses increased to $3.6 million from $3.4 million year-over-year, primarily due to higher professional fees [7][16]. Cash Position - As of September 30, 2025, the company's cash balance was $26.2 million, a decrease from $41.7 million as of December 31, 2024 [8][15]. - The company raised approximately $5.3 million by selling 5,800,000 shares and accompanying warrants on November 12, 2025 [9]. Additional Clinical Developments - The National Cancer Institute presented new clinical data at the 2025 Society for Immunotherapy of Cancer Annual Meeting, highlighting the immunological properties of PDS0101 and PDS01ADC [4]. - Preliminary results from the colorectal cancer cohort of the Phase 2 clinical trial with PDS01ADC met the criteria for expansion to Stage 2, confirming at least 6 of 9 objective responses [4].